Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
BACKGROUND: In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain. METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1797102315475304448 |
|---|---|
| author | Patel, A MacMahon, S Chalmers, J Neal, B Billot, L Woodward, M Marre, M Cooper, M Glasziou, P Grobbee, D Hamet, P Harrap, S Heller, S Liu, L Mancia, G Mogensen, C Pan, C Poulter, N Rodgers, A Williams, B Bompoint, S de Galan, B Joshi, R Travert, F |
| author_facet | Patel, A MacMahon, S Chalmers, J Neal, B Billot, L Woodward, M Marre, M Cooper, M Glasziou, P Grobbee, D Hamet, P Harrap, S Heller, S Liu, L Mancia, G Mogensen, C Pan, C Poulter, N Rodgers, A Williams, B Bompoint, S de Galan, B Joshi, R Travert, F |
| author_sort | Patel, A |
| collection | OXFORD |
| description | BACKGROUND: In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain. METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. Primary end points were composites of major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy), assessed both jointly and separately. RESULTS: After a median of 5 years of follow-up, the mean glycated hemoglobin level was lower in the intensive-control group (6.5%) than in the standard-control group (7.3%). Intensive control reduced the incidence of combined major macrovascular and microvascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), as well as that of major microvascular events (9.4% vs. 10.9%; hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarily because of a reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006), with no significant effect on retinopathy (P=0.50). There were no significant effects of the type of glucose control on major macrovascular events (hazard ratio with intensive control, 0.94; 95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes (hazard ratio with intensive control, 0.88; 95% CI, 0.74 to 1.04; P=0.12), or death from any cause (hazard ratio with intensive control, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia, although uncommon, was more common in the intensive-control group (2.7%, vs. 1.5% in the standard-control group; hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001). CONCLUSIONS: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.) |
| first_indexed | 2024-03-07T06:04:14Z |
| format | Journal article |
| id | oxford-uuid:ed493b4f-4199-4d25-a379-30326481b1ae |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:04:14Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:ed493b4f-4199-4d25-a379-30326481b1ae2022-03-27T11:23:46ZIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ed493b4f-4199-4d25-a379-30326481b1aeEnglishSymplectic Elements at Oxford2008Patel, AMacMahon, SChalmers, JNeal, BBillot, LWoodward, MMarre, MCooper, MGlasziou, PGrobbee, DHamet, PHarrap, SHeller, SLiu, LMancia, GMogensen, CPan, CPoulter, NRodgers, AWilliams, BBompoint, Sde Galan, BJoshi, RTravert, F BACKGROUND: In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain. METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. Primary end points were composites of major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy), assessed both jointly and separately. RESULTS: After a median of 5 years of follow-up, the mean glycated hemoglobin level was lower in the intensive-control group (6.5%) than in the standard-control group (7.3%). Intensive control reduced the incidence of combined major macrovascular and microvascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), as well as that of major microvascular events (9.4% vs. 10.9%; hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarily because of a reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006), with no significant effect on retinopathy (P=0.50). There were no significant effects of the type of glucose control on major macrovascular events (hazard ratio with intensive control, 0.94; 95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes (hazard ratio with intensive control, 0.88; 95% CI, 0.74 to 1.04; P=0.12), or death from any cause (hazard ratio with intensive control, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia, although uncommon, was more common in the intensive-control group (2.7%, vs. 1.5% in the standard-control group; hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001). CONCLUSIONS: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.) |
| spellingShingle | Patel, A MacMahon, S Chalmers, J Neal, B Billot, L Woodward, M Marre, M Cooper, M Glasziou, P Grobbee, D Hamet, P Harrap, S Heller, S Liu, L Mancia, G Mogensen, C Pan, C Poulter, N Rodgers, A Williams, B Bompoint, S de Galan, B Joshi, R Travert, F Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. |
| title | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. |
| title_full | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. |
| title_fullStr | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. |
| title_full_unstemmed | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. |
| title_short | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. |
| title_sort | intensive blood glucose control and vascular outcomes in patients with type 2 diabetes |
| work_keys_str_mv | AT patela intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT macmahons intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT chalmersj intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT nealb intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT billotl intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT woodwardm intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT marrem intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT cooperm intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT glaszioup intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT grobbeed intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT hametp intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT harraps intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT hellers intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT liul intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT manciag intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT mogensenc intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT panc intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT poultern intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT rodgersa intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT williamsb intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT bompoints intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT degalanb intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT joshir intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes AT travertf intensivebloodglucosecontrolandvascularoutcomesinpatientswithtype2diabetes |